Chromadex Corp. (CDXC)

3.57
0.01 0.28
NASDAQ : Process Industries
Prev Close 3.58
Open 3.52
Day Low/High 3.41 / 3.62
52 Wk Low/High 3.19 / 7.24
Volume 146.02K
Avg Volume 223.00K
Exchange NASDAQ
Shares Outstanding 46.09M
Market Cap 168.24M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Healthy Directions Has Launched NRG AdvantageTM Featuring NIAGEN(R)-the World's First And Only Commercially Available Form Of Nicotinamide Riboside (NR)

Healthy Directions Has Launched NRG AdvantageTM Featuring NIAGEN(R)-the World's First And Only Commercially Available Form Of Nicotinamide Riboside (NR)

The New Dietary Supplement Protects Against Oxidative Stress and Promotes Healthy Aging

ChromaDex Announces Exclusive Worldwide License And Supply Agreement For Anthocyanin Rich Suntava(R) Purple Corn

ChromaDex Announces Exclusive Worldwide License And Supply Agreement For Anthocyanin Rich Suntava(R) Purple Corn

ChromaDex Will Use Proprietary Suntava(R) Purple Corn to Produce a Highly Concentrated Anthocyanin Ingredient at a Price Point That Should Appeal to Mass Markets

ChromaDex Reports 1st Quarter Record Revenue As Ingredients Sales Soar 136%

ChromaDex Reports 1st Quarter Record Revenue As Ingredients Sales Soar 136%

- Total Q1 Revenue Grew 71% to $5.3 Million as Company Reports 4th Consecutive Quarter of Record Net Revenue -

ChromaDex To Host First Quarter 2015 Investor Call On Monday, May 18th At 11 Am EDT

ChromaDex To Host First Quarter 2015 Investor Call On Monday, May 18th At 11 Am EDT

Company Will Release First Quarter Earnings Report After Market Close on May 14th

Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis

Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage And Carcinogenesis

ChromaDex Holds Exclusive Worldwide Patent Rights Related to Pharmaceutical and Cosmetic Preparations of Pterostilbene for Topical Application

Insiders Trading CDXC, IHS, HFC, MWIV

Insiders Trading CDXC, IHS, HFC, MWIV

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

(Graphic: Business Wire)

(Graphic: Business Wire)

Standard & Poor’s announced today that it has commenced Factual Stock Report coverage on ChromaDex Corporation.

DiscoveryBioMed, Inc. Awarded Phase 1 SBIR Catalyst Grant Under The Recovery Act By The NIH To Discover Anti-Inflammatory Drugs

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the ...

TheStreet Quant Rating: D (Sell)